Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2009. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing details the company's issued share capital as of February 28, 2009:
- Total issued Ordinary shares: 5,662,564,079 (25p each).
- Treasury shares held: 474,194,158.
- Total voting rights: 5,188,369,921.
No comparative data for prior periods is included in this specific filing to determine material changes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (5,188,369,921) for compliance with Financial Services Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (474,194,158) as of February 28, 2009.
- Note that this filing does not contain financial performance results; refer to Form 20-F for comprehensive financial data.